pH-dependent structural transitions in cationic ionizable lipid mesophases are critical for lipid nanoparticle function.

Autor: Philipp J; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany., Dabkowska A; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Reiser A; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany., Frank K; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany., Krzysztoń R; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany., Brummer C; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany., Nickel B; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany., Blanchet CE; European Molecular Biology Laboratory Hamburg Outstation c/o Deutsches Elektronen-Synchrotron, Hamburg 22607, Germany., Sudarsan A; Institute of Physics, University of Augsburg, Augsburg 86159, Germany., Ibrahim M; Institute of Physics, University of Augsburg, Augsburg 86159, Germany., Johansson S; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Skantze P; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Skantze U; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Östman S; Animal Sciences and Technologies, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Johansson M; Animal Sciences and Technologies, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Henderson N; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Elvevold K; Marine Biotechnology, Nofima AS, Tromsø 9291, Norway., Smedsrød B; Vascular Biology Research Group, Department of Medical Biology, University of Tromsø, Tromsø 9019, Norway., Schwierz N; Institute of Physics, University of Augsburg, Augsburg 86159, Germany., Lindfors L; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden., Rädler JO; Faculty of Physics and Center for NanoScience, Ludwig Maximilians-University, Munich 80539, Germany.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2023 Dec 12; Vol. 120 (50), pp. e2310491120. Date of Electronic Publication: 2023 Dec 06.

High Sensitivity Detection of a Solubility Limiting Surface Transformation of Drug Particles by DNP SENS.

Autor: Viger-Gravel J; Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland; Organic Chemistry Department, School of Chemistry and Biochemistry, University of Geneva, CH-1211 Geneva, Switzerland., Pinon AC; Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland; Swedish NMR Center, 413 90 Gothenburg, Sweden., Björgvinsdóttir S; Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland., Skantze U; Advanced Drug Delivery, Pharmaceutical Science, AstraZeneca, Gothenburg, Sweden., Svensk Ankarberg A; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden., Von Corswant C; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden., Schantz S; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden., Emsley L; Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. Electronic address: lyndon.emsley@epfl.ch.

Publikováno v: Journal of pharmaceutical sciences [J Pharm Sci] 2021 Jun; Vol. 110 (6), pp. 2452-2456. Date of Electronic Publication: 2021 Jan 06.

Core-Shell Structure of Organic Crystalline Nanoparticles Determined by Relayed Dynamic Nuclear Polarization NMR.

Autor: Pinon AC; Institut des Sciences et Ingénierie Chimiques , Ecole Polytechnique Fédérale de Lausanne (EPFL) , CH-1015 Lausanne , Switzerland., Skantze U; Pharmaceutical Sciences, IMED Biotech Unit , AstraZeneca , Gothenburg , Sweden., Viger-Gravel J; Institut des Sciences et Ingénierie Chimiques , Ecole Polytechnique Fédérale de Lausanne (EPFL) , CH-1015 Lausanne , Switzerland., Schantz S; Pharmaceutical Technology & Development , AstraZeneca , Gothenburg , Sweden., Emsley L; Institut des Sciences et Ingénierie Chimiques , Ecole Polytechnique Fédérale de Lausanne (EPFL) , CH-1015 Lausanne , Switzerland.

Publikováno v: The journal of physical chemistry. A [J Phys Chem A] 2018 Nov 08; Vol. 122 (44), pp. 8802-8807. Date of Electronic Publication: 2018 Oct 26.

Nanocrystal formulations of a poorly soluble drug. 2. Evaluation of nanocrystal liver uptake and distribution after intravenous administration to mice.

Autor: Sigfridsson K; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden. Electronic address: carl-gustav.sigfridsson@astrazeneca.com., Skantze P; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden., Skantze U; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden., Svensson L; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden., Löfgren L; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden., Nordell P; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden., Michaëlsson E; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden., Smedsrød B; D'Liver AS, 9294 Tromsø, Norway; Vascular Biology Research Group, Department of Medical Biology, University of Tromsø, Tromsø, Norway., Fuglesteg B; D'Liver AS, 9294 Tromsø, Norway., Elvevold K; D'Liver AS, 9294 Tromsø, Norway., Lindfors L; AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden.

Publikováno v: International journal of pharmaceutics [Int J Pharm] 2017 May 30; Vol. 524 (1-2), pp. 248-256. Date of Electronic Publication: 2017 Mar 31.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.